Back to top
more

Sangamo Therapeutics (SGMO)

(Delayed Data from NSDQ)

$0.49 USD

0.49
1,157,568

-0.03 (-5.36%)

Updated Apr 24, 2024 04:00 PM ET

After-Market: $0.49 0.00 (-0.61%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value B Growth D Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 31% (78 out of 252)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for SGMO

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

0 items in cart

Sangamo Therapeutics, Inc. [SGMO]

Reports for Purchase

Showing records 161 - 180 ( 321 total )

Company: Sangamo Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 161

02/06/2017

Daily Note

Pages: 45

February and Full Year 2017 Catalysts for Emerging Pharmaceuticals

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 100.00

Research Provided by a Third Party

Company: Sangamo Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 162

01/03/2017

Daily Note

Pages: 40

January and Full Year 2017 Catalysts for Emerging Pharmaceuticals

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 75.00

Research Provided by a Third Party

Company: Sangamo Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 163

12/05/2016

Daily Note

Pages: 39

December and Full Year 2017 Catalysts for Emerging Pharmaceuticals

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 75.00

Research Provided by a Third Party

Company: Sangamo Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 164

11/28/2016

Industry Report

Pages: 10

ASH 2016: Additional Abstracts and Sessions of Interest

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Company: Sangamo Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 165

11/07/2016

Daily Note

Pages: 44

November and Full Year 2016 Catalysts for Emerging Pharmaceuticals

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 100.00

Research Provided by a Third Party

Company: Sangamo Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 166

10/31/2016

Company Report

Pages: 7

Downgrading to NEUTRAL - Reducing PT to $4; Management''s Overhaul Solidifies Foundation but Creates Pipeline Gap - Lack of Catalysts Until 2018

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: Sangamo Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 167

10/23/2016

Industry Report

Pages: 6

The Week Ahead in Life Sciences - Upcoming Events for the Week of Oct 24

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Company: Sangamo Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 168

10/04/2016

Daily Note

Pages: 45

October and Full Year 2016 Catalysts for Emerging Pharmaceuticals

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 100.00

Research Provided by a Third Party

Company: Sangamo Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 169

09/01/2016

Daily Note

Pages: 44

September and Full Year 2016 Catalysts for Emerging Pharmaceuticals

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 100.00

Research Provided by a Third Party

Company: Sangamo Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 170

08/03/2016

Company Report

Pages: 7

Q2 Financials Update; Sufficiently Capitalized to Fund Operations through Value Creating Catalysts

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: Sangamo Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 171

08/01/2016

Daily Note

Pages: 46

August and Full Year 2016 Catalysts for Emerging Pharmaceuticals

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 100.00

Research Provided by a Third Party

Company: Sangamo Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 172

05/31/2016

Daily Note

Pages: 43

June and Full Year 2016 Catalysts for Emerging Pharmaceuticals

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 100.00

Research Provided by a Third Party

Company: Sangamo Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 173

05/09/2016

Daily Note

Pages: 43

May and Full Year 2016 Catalysts for Emerging Pharmaceuticals

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 100.00

Research Provided by a Third Party

Company: Sangamo Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 174

05/06/2016

Company Report

Pages: 7

Q1 Financials Update; Hemophilia B and MPS I Trials Are Set to Initiate; Reiterate OUTPERFORM

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: Sangamo Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 175

04/29/2016

Industry Report

Pages: 6

The Week Ahead in Life Sciences

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Company: Sangamo Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 176

04/01/2016

Daily Note

Pages: 42

April and Full Year 2016 Catalysts for Emerging Pharmaceuticals

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 100.00

Research Provided by a Third Party

Company: Sangamo Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 177

03/03/2016

Daily Note

Pages: 5

Preclinical Results from IVPRP Approach in Hurler and Hunter Syndrome Models Suggest Potential Breakthrough To Us; Reiterate OUTPERFORM

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 10.00

Research Provided by a Third Party

Company: Sangamo Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 178

03/03/2016

Industry Report

Pages: 43

March and Full Year 2016 Catalysts for Emerging Pharmaceuticals

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 100.00

Research Provided by a Third Party

Company: Sangamo Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 179

02/12/2016

Industry Report

Pages: 5

The Week Ahead in Life Sciences - Upcoming Events for the Week of Feb. 15

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 10.00

Research Provided by a Third Party

Company: Sangamo Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 180

02/10/2016

Company Report

Pages: 7

Q4/FY:15 Update; Gene Editing Programs Begin Clinical Testing in 2016; Reiterate OUTPERFORM and $30 PT

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party